Rising Demand for Biomarkers: Fueling Growth in the Global Antibodies and Reagents Market

The Research Antibodies and Reagents Market was valued at $4.08 billion in 2023 and is projected to grow to $6.77 billion by 2031. It is estimated to reach $4.36 billion in 2024, with a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031.

Biomarkers are measurable indicators of disease severity, playing a crucial role in targeted therapies by enabling accurate predictions of clinical outcomes across various populations and treatments. Recently, the demand for new biomarker identification has been on the rise, driven by the need for selective therapies, lower clinical trial costs, and the growing prevalence of chronic diseases, particularly within an aging population.

Download Sample Report Here:  https://www.meticulousresearch.com/download-sample-report/cp_id=5055

According to data from the United Nations and the World Bank, the global population aged 60 years or older increased from 566.9 million in 2013 to 673.6 million in 2018. Furthermore, the number of people aged 80 and above is projected to nearly triple by 2050, rising from 143 million to 426 million. In 2017, over two-thirds of the world’s elderly population resided in developing regions, and this trend is expected to continue. Between 2017 and 2050, the number of people aged 60 and older in developing regions is predicted to more than double, from 652 million to 1.7 billion. This aging demographic is expected to contribute to a rise in chronic diseases, such as cancer.

Cancer incidence has surged significantly. In 2012, around 14.1 million new cancer cases were diagnosed globally, a figure that increased by approximately 28% to 18.1 million by 2018, according to GLOBOCAN. By 2040, this number is projected to rise by 109.5%, reaching 29.5 million new cases. Additionally, cancer-related mortality has also risen; in 2012, 8.2 million deaths were attributed to cancer, increasing by 17% to 9.6 million in 2018. Projections estimate that cancer mortality will increase by 58.5% by 2030, with 13 million deaths, and by 100% by 2040, with 16.4 million deaths. As cancer cases and mortality rates continue to rise, there is an increasing demand for targeted therapies, such as antibodies, which is expected to drive growth in the research antibodies and reagents market.

Browse in Depth : https://www.meticulousresearch.com/product/research-antibodies-and-reagents-market-5055

Emerging economies, particularly in regions like Latin America, have seen a continuous rise in cancer incidence. In 2018, Latin America and the Caribbean recorded 1.4 million new cancer cases, a figure expected to grow by 40.1% to 1.98 million by 2030. By 2040, this number could reach 2.52 million cases. Similarly, cancer-related deaths in the region, which stood at 672,758 in 2018, are expected to nearly double, reaching 1.3 million by 2040. This increase in cancer prevalence has fueled demand for targeted medicines, leading to greater investment in drug discovery and development.

Governments in developing regions are also increasing their investments in healthcare infrastructure, which is expected to further boost demand for antibodies and related reagents. For example, the Indian healthcare sector is expanding rapidly, driven by both public and private investment. According to the Indian Brand Equity Foundation (IBEF), India is a key global provider of antiretroviral drugs, with over 3,500 hospitals and 25,000 dispensaries across the country. Similarly, China’s 13th Five-Year Plan, launched in 2016, outlined reforms aimed at improving healthcare services and expanding access to comprehensive care in both urban and rural areas by 2020. Additionally, federal law changes in Brazil, implemented in 2015, have opened the door to foreign investment in hospitals and clinics, boosting funding for healthcare infrastructure in the region.

Advancements in biomarker discovery are also driving growth in the antibodies market. For instance, protein array technology, based on antibodies, was used for biomarker discovery in lupus in 2016, according to the Proteomics Clinical Applications journal. Antibody-based assays have also been used to identify oral cancer biomarkers in saliva, according to the Oral Cancer Foundation. Moreover, the Royal College of Surgeons in Ireland discovered blood biomarkers in drug-free schizophrenia patients using multiplex and proteomics immunoassays. A novel method of whole auto-antibody mapping has also emerged, facilitating scalable biomarker discovery in systemic autoimmune diseases. These developments have led to the rise of biomarker-based cancer diagnostics and therapies, such as HER2-targeted therapy for breast cancer through immunohistochemistry.

The increasing prevalence of biomarker identification using immunohistochemistry and immunoassays has boosted the adoption of research antibodies, creating significant opportunities for market vendors. The global research antibodies and reagents market is projected to grow at a CAGR of 5.6%, reaching $6.32 billion by 2027, according to Meticulous Research.

Quick Buy:  https://www.meticulousresearch.com/Checkout/11998366

Research Antibodies and Reagents Market Report Summary:

About Meticulous Research®

Meticulous Research® is a leading provider of comprehensive market intelligence, offering actionable insights and analysis across various industries. Our reports empower businesses to make informed decisions, drive growth, and remain competitive in a rapidly evolving marketplace.

Contact:

Meticulous Market Research Pvt. Ltd.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research